Seres Therapeutics Inc
NASDAQ:MCRB 4:00:00 PM EDT
| Market Cap (Intraday) | 156.03M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $17.67 |
| 50-Day MA | $16.12 |
| 200-Day MA | $13.75 |
Seres Therapeutics Inc Stock, NASDAQ:MCRB
101 Cambridge Park Drive, 4th floor, Cambridge, Massachusetts 02140
United States of America
Phone: +1.617.945.9626
Number of Employees: 233
Description
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.